comparemela.com

Latest Breaking News On - Research associate in pediatric metabolic diseases - Page 1 : comparemela.com

Evinacumab Cuts LDL-C in Children With Homozygous Familial Hypercholesterolemia

Positive results were announced from a phase 3 trial evaluating evinacumab in children 5 to 11 years with HoFH.

Noord hollandM doortje reijmanResearch associate in pediatric metabolic diseasesAmsterdam university medical centerDrug administrationResearch associatePediatric metabolic diseasesAmsterdam university medical

Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol

/PRNewswire/ Children already on other lipid-lowering therapies entered the trial with dangerously high LDL-C (264 mg/dL on average), and 79% saw their.

Noord hollandM doortje reijmanGeorged yancopoulosTammy allenRegeneron velocimmuneRegeneron pharmaceuticals incRegeneron genetics centerEuropean commissionEuropean atherosclerosis society pediatric familial hypercholesterolemiaDrug administrationTeva pharmaceutical industries ltdExchange commissionVelocimmune technologyResearch associate in pediatric metabolic diseasesAmsterdam university medical centerResearch associate

vimarsana © 2020. All Rights Reserved.